Combination Strategies A Common Thread In NASH R&D

BOSTON – With hepatitis C on the decline, non-alcoholic steatohepatitis is becoming the focus of liver disease R&D. While Intercept Pharmaceuticals Inc. and Genfit SA have the early lead in drug development, recent deal-making by Allergan PLC and Bristol-Myers Squibb Co., as well as a reshuffled strategy at Gilead Sciences Inc., appear to have the competition in flux.

Intercept continues to lead the race to get the first drug approved for non-alcoholic steatohepatitis (NASH) with Ocaliva – but, not for the first time, Tobira Therapeutics Inc